EP1937851A4 - Methods and compositions for generating bioactive assemblies of increased complexity and uses - Google Patents

Methods and compositions for generating bioactive assemblies of increased complexity and uses

Info

Publication number
EP1937851A4
EP1937851A4 EP06785922A EP06785922A EP1937851A4 EP 1937851 A4 EP1937851 A4 EP 1937851A4 EP 06785922 A EP06785922 A EP 06785922A EP 06785922 A EP06785922 A EP 06785922A EP 1937851 A4 EP1937851 A4 EP 1937851A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
increased complexity
bioactive assemblies
generating bioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06785922A
Other languages
German (de)
French (fr)
Other versions
EP1937851A2 (en
Inventor
Chien-Hsing Chang
David M Goldenberg
William J Mcbride
Edmund A Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IBC Pharmaceuticals Inc
Original Assignee
IBC Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/389,358 external-priority patent/US7550143B2/en
Priority claimed from PCT/US2006/010762 external-priority patent/WO2006107617A2/en
Priority claimed from PCT/US2006/012084 external-priority patent/WO2006107786A2/en
Application filed by IBC Pharmaceuticals Inc filed Critical IBC Pharmaceuticals Inc
Publication of EP1937851A2 publication Critical patent/EP1937851A2/en
Publication of EP1937851A4 publication Critical patent/EP1937851A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
EP06785922A 2005-10-19 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses Withdrawn EP1937851A4 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US75119605P 2005-12-16 2005-12-16
US78233206P 2006-03-14 2006-03-14
US11/389,358 US7550143B2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PCT/US2006/010762 WO2006107617A2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US11/391,584 US7521056B2 (en) 2005-04-06 2006-03-28 Stably tethered structures of defined compositions with multiple functions or binding specificities
PCT/US2006/012084 WO2006107786A2 (en) 2005-04-06 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities
PCT/US2006/025499 WO2007046893A2 (en) 2005-10-19 2006-06-29 Methods for generating bioactive assemblies and uses thereof

Publications (2)

Publication Number Publication Date
EP1937851A2 EP1937851A2 (en) 2008-07-02
EP1937851A4 true EP1937851A4 (en) 2010-08-25

Family

ID=40666724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06785922A Withdrawn EP1937851A4 (en) 2005-10-19 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses

Country Status (5)

Country Link
EP (1) EP1937851A4 (en)
JP (1) JP5231231B2 (en)
AU (1) AU2006302848C1 (en)
CA (1) CA2607056C (en)
WO (1) WO2007046893A2 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
JP5699362B2 (en) * 2008-04-10 2015-04-08 アイビーシー ファーマスーティカルズ，インコーポレイテッド Modular method for preparing tetrameric cytokines with improved pharmacokinetics by dock-and-lock (DNL) technology
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
CN102123737B (en) 2008-06-13 2014-01-01 西马生物医学计划公司 Conjugates for the administration of biologically active compounds
AU2009282830B2 (en) * 2008-08-20 2013-11-28 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
WO2010033249A2 (en) 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
CN102325790A (en) 2008-12-03 2012-01-18 西马生物医学计划公司 Use of phenol-soluble modulins for vaccine development
EP2393514B1 (en) * 2009-02-06 2017-12-20 Sichuan Huiyu Pharmaceutical Co., Ltd. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
IN2012DN01662A (en) * 2009-08-31 2015-06-05 Immunomedics Inc
CN102481348A (en) * 2009-08-31 2012-05-30 Ibc药品公司 Bispecific immunocytokine docking-and-locking (DNL) complexes and therapeutic uses thereof
EP2476440B1 (en) 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Therapeutic compositions for the treatment of hpv-induced diseases
CN102573902A (en) * 2009-11-05 2012-07-11 分子医学和免疫学中心 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
EP2509630A4 (en) * 2009-12-09 2013-07-17 Immunomedics Inc Delivery system for cytotoxic drugs by bispecific antibody pretargeting
EP2509629A4 (en) * 2009-12-09 2013-06-26 Ibc Pharmaceuticals Inc Dock-and-lock (dnl) complexes for delivery of interference rna
EP2518078B1 (en) * 2009-12-15 2020-05-20 Choe, Muhyeon Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
JP5786204B2 (en) * 2010-01-19 2015-09-30 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． A novel class of monospecific and bispecific humanized antibodies targeting the insulin-like growth factor type I receptor (IGF-1R)
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
AU2011276443A1 (en) 2010-06-29 2013-01-31 Covidien Lp Microwave-powered reactor and method for in situ forming implants
EP2588153A2 (en) 2010-07-01 2013-05-08 Sofradim Production Medical device with predefined activated cellular integration
CA2808211C (en) * 2010-08-17 2018-08-28 Ibc Pharmaceuticals, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
EP2635300A4 (en) * 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN103160513B (en) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 MUC1 protein nucleic acid aptamer, complex, composition and purposes thereof
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
WO2013181087A2 (en) 2012-06-01 2013-12-05 Ibc Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
CN102703453B (en) * 2012-06-13 2013-10-30 江南大学 DNA aptamer specifically recognizing streptomycin and application of DNA aptamer
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
ITRM20130138A1 (en) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche ASSEMBLED INCLUDING A LIGHT ABSORBER IN THE INFRARED NEIGHBOR ENTITLELY TIED TO AN INHIBITOR OF THE CARBON DIVE
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
EP3062818B1 (en) 2013-11-01 2019-09-11 IBC Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
FR3017714A1 (en) * 2014-02-18 2015-08-21 Biomerieux Sa METHOD AND KIT FOR DETERMINING THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
WO2016122702A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
CN104558174A (en) * 2015-01-29 2015-04-29 东南大学 Testosterone-orientated specific nano-antibody and application thereof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US9687547B2 (en) 2015-05-28 2017-06-27 Immunomedics, Inc. T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
SI3328419T1 (en) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-binding molecules and methods for their use
RU2731202C2 (en) 2015-10-08 2020-08-31 Макродженикс, Инк. Combined therapy for cancer treatment
CN108289920A (en) * 2015-10-12 2018-07-17 汉阳大学校产学协力团 Adenoviral complexes for gene transfer and gene therapy
JP6841430B2 (en) * 2015-12-04 2021-03-10 全薬工業株式会社 Anti-IL-17 aptamer with improved blood retention
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN109195620B (en) 2016-04-07 2022-06-28 约翰霍普金斯大学 Compositions and methods for treating pancreatitis and pain with death receptor agonists
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
BR112019012950A2 (en) 2016-12-23 2019-11-26 Macrogenics Inc adam9 binding molecule, pharmaceutical composition, use of the adam9 binding molecule and method for treating a disease or condition associated with or characterized by the expression of adam9 in an individual
BR112019017628A2 (en) 2017-02-24 2020-07-07 Macrogenics, Inc. cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN109771658B (en) * 2017-11-14 2021-12-10 博瑞生物医药（苏州）股份有限公司 Targeted multi-arm conjugates
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
KR102101561B1 (en) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 Angiogenesis target constrast medium and a method for producing the same
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
EP4021909A4 (en) 2019-08-29 2023-08-30 David C. Martin BIOFUNCTIONAL THIOPHENE MONOMERS
CN115279403A (en) 2020-02-21 2022-11-01 宏观基因有限公司 CD137 binding molecules and uses thereof
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CN112156194B (en) * 2020-09-29 2023-01-24 中国工程物理研究院核物理与化学研究所 Removing method 177 Method for endotoxin in Lu solution
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CN115976196B (en) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3 as a biomarker and therapeutic target for pulmonary arterial hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2006107617A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501219A (en) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION.
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JP4113670B2 (en) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド Use of bispecific antibodies for pre-targeting diagnosis and pretargeting therapy
US7060506B2 (en) * 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
CA2503787A1 (en) * 2002-11-05 2004-05-27 Regeneron Pharmaceuticals, Inc. Methods of isolation of active compounds and activated targets
DE602004001395T2 (en) * 2003-02-13 2007-08-09 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. RHESUS CARCINOEMBRYONAL ANTIGEN, THIS CODING NUCLEOTIDE AND USES THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2006107617A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BANKY P ET AL: "Dimerization/docking domain of the type Ialpha regulatory subunit of cAMP-dependent protein kinase. Requirements for dimerization and docking are distinct but overlapping.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 DEC 1998, vol. 273, no. 52, 25 December 1998 (1998-12-25), pages 35048 - 35055, XP002555878, ISSN: 0021-9258 *
CHANG CHIEN-HSING ET AL: "The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 SEP 2007 LNKD- PUBMED:17875793, vol. 13, no. 18 Pt 2, 15 September 2007 (2007-09-15), pages 5586s - 5591s, XP009112546, ISSN: 1078-0432, DOI: 10.1158/1078-0432 *
CHIEN-HSING CHANG ET AL: "A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon-[alpha]2b", BIOCONJUGATE CHEMISTRY, vol. 20, no. 10, 21 October 2009 (2009-10-21), pages 1899 - 1907, XP055022032, ISSN: 1043-1802, DOI: 10.1021/bc9001773 *
DEYEV S M ET AL: "Design of multivalent complexes using the barnase-barstar module", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 21, no. 12, 1 December 2003 (2003-12-01), pages 1486 - 1492, XP002372739, ISSN: 1087-0156 *
EDMUND A ROSSI ET AL: "Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics", vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8384 - 8392, XP002698652, ISSN: 0008-5472, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/68/20/8384> DOI: 10.1158/0008-5472.CAN-08-2033 *
GOLDENBERG DAVID M ET AL: "Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE JAN 2008 LNKD- PUBMED:18077530, vol. 49, no. 1, January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
NEWLON M G ET AL: "The molecular basis for protein kinase A anchoring revealed by solution NMR.", NATURE STRUCTURAL BIOLOGY MAR 1999, vol. 6, no. 3, March 1999 (1999-03-01), pages 222 - 227, XP002555877, ISSN: 1072-8368 *
OYEN O ET AL: "Human testis cDNA for the regulatory subunit RIIalpha of CAMP-dependent protein kinase encodes an alternate amino-terminal region", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 246, no. 1-2, 27 March 1989 (1989-03-27), pages 57 - 64, XP025652754, ISSN: 0014-5793, [retrieved on 19890327] *
PLUCKTHUN A ET AL: "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 2, 1 June 1997 (1997-06-01), pages 83 - 105, XP004126672, ISSN: 1380-2933 *
ROSSI E A ET AL: "Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, PART 2, 1 September 2003 (2003-09-01), pages 3886S - 3896S, XP002259779, ISSN: 1078-0432 *
ROSSI EDMUND A ET AL: "A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.", CANCER RESEARCH 1 OCT 2010 LNKD- PUBMED:20876805, vol. 70, no. 19, 1 October 2010 (2010-10-01), pages 7600 - 7609, ISSN: 1538-7445 *
ROSSI EDMUND A ET AL: "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.", BLOOD 29 OCT 2009 LNKD- PUBMED:19710501, vol. 114, no. 18, 29 October 2009 (2009-10-29), pages 3864 - 3871, XP055215756, ISSN: 1528-0020, DOI: 10.1182/blood-2009-06-228890 *
SHARKEY ROBERT M ET AL: "Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS FEB 2010 LNKD- PUBMED:20187791, vol. 25, no. 1, February 2010 (2010-02-01), pages 1 - 12, ISSN: 1557-8852 *
SHARKEY ROBERT M ET AL: "Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.", CANCER RESEARCH 1 JUL 2008 LNKD- PUBMED:18593929, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 5282 - 5290, XP055273512, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-08-0037 *
SHARKEY ROBERT M ET AL: "Optimizing bispecific antibody pretargeting for use in radioimmunotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, 1 September 2003 (2003-09-01), pages 3897S - 3913S, XP009099022, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
CA2607056C (en) 2015-11-24
JP5231231B2 (en) 2013-07-10
AU2006302848B2 (en) 2012-02-23
CA2607056A1 (en) 2007-04-26
WO2007046893A3 (en) 2009-04-23
WO2007046893A2 (en) 2007-04-26
AU2006302848A1 (en) 2007-04-26
AU2006302848C1 (en) 2012-08-02
JP2009517337A (en) 2009-04-30
EP1937851A2 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
EP1937851A4 (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
PL1845803T3 (en) Method for the prepration of spray-dried compositions and their uses
PL3398606T3 (en) Microalgae-derived compositions for improving the health and appearance of skin
IL186973A0 (en) Compositions and methods for treatment for neoplasms
PL3263581T3 (en) Compositions and methods for immunomodulation in an organism
ZA200805640B (en) Terpene-containing compositions and methods of making and using them
IL191072A0 (en) Therapeutic compositions and methods
IL185540A0 (en) Compositions and methods for treating acne
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL190885A0 (en) Immunogenic compositions and methods of use
ZA200710983B (en) Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
GB0522287D0 (en) Method and compositions
IL190520A0 (en) Compositions and methods for treatment of autoimmune
EP1968526A4 (en) Foamable dental compositions and methods
IL190583A0 (en) Pth formulations and methods of use
EP1937075A4 (en) Synergistic composition and method of use
GB0524927D0 (en) Compositions and method
ZA200707529B (en) Pro-fragrance and pro-flavorant compositions
GB0520930D0 (en) Composition and method of use
EP2046109A4 (en) Photosyntheticorganisms and compositions and methods of generating same
GB2423081B (en) Pro-fragrance and pro-flavorant compositions
GB0511235D0 (en) Compositions and method
EP1874795A4 (en) Compositions and uses of amooranin compounds
GB0504657D0 (en) Compositions and methods of treatment
IL196588A0 (en) Photosyntheticorganisms and compositions and methods of generating same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071018

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20090623BHEP

Ipc: C07K 16/46 20060101ALI20090623BHEP

Ipc: A61K 39/395 20060101ALI20090623BHEP

Ipc: A61K 38/16 20060101ALI20090623BHEP

Ipc: A61K 31/00 20060101ALI20090623BHEP

Ipc: C07K 19/00 20060101ALI20090623BHEP

Ipc: C07K 17/00 20060101ALI20090623BHEP

Ipc: A61K 103/00 20060101ALI20090623BHEP

Ipc: A61K 51/00 20060101AFI20090623BHEP

Ipc: C07K 14/00 20060101ALI20090623BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100722

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20100716BHEP

Ipc: C07K 16/28 20060101AFI20100716BHEP

17Q First examination report despatched

Effective date: 20110727

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180412